RegeneRx Biopharmaceuticals, Inc.
http://www.regenerx.com
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From RegeneRx Biopharmaceuticals, Inc.
Roche’s Novel Ranibizumab Implant Among Myriad New Filings In EU
The European Medicines Agency has added 13 new drugs to its list of products that are under review for potential pan-EU marketing approval.
Asia Deal Watch: Heartseed Licenses Lead Cell Therapy Candidate To Novo Nordisk
Novo gets worldwide development and commercial rights except for Heartseed’s home market in Japan. LianBio unveils licensing partnerships with Lyra, Landos and Nanobiotix.
Samsung Bioepis Breaks Down Biosimilar Experiences In Europe And US
Samsung Bioepis reiterated that the US pharma market is “the most fragmented and the most complicated market in the world” as it discussed its biosimilar fortunes in Europe.
Lupin Pursues India Approval For Lucentis Biosimilar, COVID-19 Opportunities
A bit late to the table, Lupin is exploring voluntary licensing for COVID-19 therapeutics and vaccines from Gilead’s remdesivir to Merck’s molnupiravir. Meanwhile, pricing for a biosimilar to Lucentis, which has been filed for approval in India, will be keenly watched.
Company Information
- Industry
- Pharmaceuticals
-
Medical Devices
- Biomaterials
-
Biotechnology
- Large Molecule